(STRO) – Management Comments
-
Sutro Biopharma (STRO) Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
-
Sutro Biopharma Inc. (STRO) Reports Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
-
-
-
-
-
-
-
-
-
-
Back to STRO Stock Lookup